Woman's Despair as NHS Pauses Botox Treatment for Rare Digestive Condition
A woman suffering from a rare and painful digestive condition has described the NHS decision to pause her Botox treatment as 'soul-destroying'. Vicky, 44, from Wolverhampton, was diagnosed with Sphincter of Oddi Dysfunction a decade ago, a disorder that causes severe pain when digestive muscles spasm uncontrollably.
Understanding Sphincter of Oddi Dysfunction
The condition leads to a dangerous buildup of bile, resulting in symptoms that Vicky compares to having jaundice. Since 2017, she has relied on regular Botox injections into her sphincter and pancreatic region, which have provided significant relief from the debilitating pain.
'I don't have to take as much heavy-duty medication and I'm able to hold down a job,' Vicky explained, highlighting how the treatment has improved her quality of life. However, University Hospitals Birmingham NHS Foundation Trust has now paused this treatment to conduct further research into its effectiveness.
Trust's Decision and Patient Concerns
The trust states that Botox for this specific condition is not approved by the National Institute for Health and Care Excellence (NICE) and lacks support from specialist clinical bodies. This pause leaves Vicky fearing a return to daily anti-sickness medication and high-strength painkillers, which she had managed to reduce thanks to the Botox injections.
Private treatment options are available but come with a steep price tag of approximately £3,000 every three to four months, making them unaffordable for most patients. Alternative treatments, such as stent procedures, carry significant risks, including a 90 per cent chance of severe pancreatitis for patients like Vicky.
Impact of Treatment Pause
During the pandemic, when Vicky was unable to access her Botox treatment, her symptoms worsened dramatically. 'To have gone through that, and to find a treatment and then have it taken away from you is soul destroying,' she said, expressing her deep frustration and despair.
The pause in treatment raises concerns about the availability of effective care for rare conditions within the NHS. Patients with Sphincter of Oddi Dysfunction now face uncertain futures as the trust evaluates the treatment's efficacy, leaving many to grapple with pain and limited options.
